Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101. Proceedings of the National Academy of Sciences of the United States of America Scholz, A., DeFalco, J., Leung, Y., Aydin, I. T., Czupalla, C. J., Cao, W., Santos, D., Vad, N., Lippow, S. M., Baia, G., Harbell, M., Sapugay, J., Zhang, D., Wu, D., Wechsler, E., Ye, A. Z., Wu, J. W., Peng, X., Vivian, J., Kaplan, H., Collins, R., Nguyen, N., Whidden, M., Kim, D., Millward, C., Benjamin, J., Greenberg, N. M., Serafini, T. A., Emerling, D. E., Steinman, L., Robinson, W. H., Manning-Bog, A. 2022; 119 (19): e2123483119

Abstract

SignificanceA target-agnostic approach that harnesses the human antitumor immune response to find potential anticancer lead antibodies and their targets was used to generate ATRC-101, an engineered version of a tumor-targeting antibody identified from a patient with non-small cell lung cancer experiencing an ongoing antitumor immune response. ATRC-101 is an antibody that targets an extracellular, tumor-specific ribonucleoprotein complex. Here, we describe the extracellular binding of this complex and antitumor activity of ATRC-101 in murine models. Preclinical data suggest a mechanism of action in which ATRC-101 activates myeloid cells of the innate immune system, leading to an adaptive immune response that yields its antitumor activity. These data have led to an ongoing phase 1 trial in patients with advanced solid tumors.

View details for DOI 10.1073/pnas.2123483119

View details for PubMedID 35507878